This unexpectedly low prevalence of BRCA1 Exon 13 duplication contradicts previous prevalence data from North American/European cohorts of patients at risk of hereditary breast and/or ovarian cancer, where this large rearrangement was the fourth most common germline BRCA1 pathogenic variant [35,36,37]. This evidence concerns the gene BRCA1 and ovarian cancer.